Loading...
PhD Simona Kranjc Brezar

PhD Simona Kranjc Brezar
no.: 19058 source: ARIS

researcher – active in research organisation
Phone number (01) 587 96 07
  skranjcat signonko-i.si
Foreign language skills
Research activity

Code Science Field Subfield
3.00.00  Medical sciences     
3.04.00  Medical sciences  Oncology   
Keywords
Experimental oncology, tumor biology, radiation, chemotherapy,electrochemotherapy
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Points
939.04
A''
0
A'
445.94
A1/2
574.91
CI10
966
CImax
99
h10
16
A1
3.18
A3
4.46
Data for the last 5 years (citations for the last 10 years) on October 15, 2025; Data for score A3 calculation refer to period 2020-2024 (2019, 2020, 2021, 2022, 2023)
Data for ARIS tenders ( 23.05.2022 – Target research programmes, archive )
Database Linked records Citations Pure citations Average pure citations
WoS 90  1,597  1,037  11.52 
Scopus 92  1,899  1,279  13.9 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 PhD Tanja Jesenko   Bologna doctoral studies  11/1/2010 - 4/30/2014  33227 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
  B. Sc.   Biology  SI University of Ljubljana, Biotechnical Faculty 1998 
Master's degree  M. Sc.     SI University of Ljubljana, Faculty of Medicine 2001 
Doctoral degree  Ph. D.     SI University of Ljubljana, Faculty of Medicine 2003 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group Date of employment Position Role Title
Full time employment (100%, RD:100%)  Institute of Oncology Ljubljana  Department of research  11/1/1998    Researcher   
Research projects Legend
source: ARIS
no. Code Title Period Head No. of publications
1. J3-60068  Circulating tumor cell translational research platform.   1/1/2025 - 12/31/2027  PhD Tanja Jesenko   2,923 
2. J1-60017  Perfusion, Edema, and Necrosis Evaluation using OCT for Tumor Outcome Measures   1/1/2025 - 12/31/2027  PhD Jošt Stergar   2,743 
3. J3-50108  DEBIO 1143 has a potential to increase effectiveness of electrochemotherapy and radiotherapy in HPV positive and HPV negative Head and Neck Cancers   10/1/2023 - 9/30/2026  PhD Katarina Žnidar   2,397 
4. J4-50150  Erythrocyte membrane-based nanocarriers for gene silencing cancer therapy   10/1/2023 - 9/30/2026  PhD Nina Kostevšek   4,220 
5. L3-50111  Gene immuno-therapy of solid tumors based on mRNA encoding interleukin-12: So-rIL   10/1/2023 - 9/30/2026  PhD Maja Čemažar   3,048 
6. J3-50110  Intratumoral mRNA electrotransfer: establishment and preclinical proof of concept   10/1/2023 - 9/30/2026  PhD Katja Uršič Valentinuzzi   3,367 
7. J2-50068  Safety and efficacy of high frequency electrochemotherapy - clinical device development   10/1/2023 - 9/30/2026  PhD Matej Reberšek   3,729 
8. J7-4635  MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy   10/1/2022 - 9/30/2026  PhD Lucija Peterlin Mašič   6,640 
9. L7-4491  Development of integrated multi-channel artificial nose for detection of cancer   10/1/2022 - 9/30/2025  PhD Igor Muševič   5,928 
10. J1-4417  Development of novel small molecule Toll-like receptors 7 and 8 modulators for cancer immunotherapy   10/1/2022 - 9/30/2025  PhD Matej Sova   4,257 
11. J3-3083  Vascularization and vascular effects as predictive factors for local ablative techniques   10/1/2021 - 9/30/2025  PhD Gregor Serša   7,319 
12. BI-AT/23-24-027  Evaluation of a novel mouse HPV positive oral squamous cell carcinoma model   1/1/2023 - 6/30/2025  PhD Simona Kranjc Brezar   363 
13. J3-2529  Role of endothelium in tumor response to radiotherapy   9/1/2020 - 8/31/2023  PhD Boštjan Markelc   3,723 
14. J3-9269  Clinico-pharmacological approach to optimize the therapeutic bleomycin concentration in patients undergoing electrochemotherapy   7/1/2018 - 6/30/2021  PhD Gregor Serša   3,831 
15. J3-7460  Irradiation dose modifying factor of squamous cell carcinoma of the oropharynx infected by human papillomavirus: an in vitro and in vivo study in laboratory mouse tumor model   1/1/2016 - 12/31/2018  PhD Primož Strojan   4,561 
16. J3-6793  Novi pristopi radiosenzibilizacije tumorjev z gensko terapijo (Slovene)   7/1/2014 - 6/30/2017  PhD Gregor Serša   5,483 
17. J1-6744  Razvoj polimerov z molekularnimi odtisi in njihova uporaba na področju okoljske in bio-analitike (Slovene)   7/1/2014 - 6/30/2017  PhD Tina Kosjek   5,213 
18. J3-6796  Translacijska onkologija: razvoj in validacija imunsko genske terapije z interleukinom-12 v kombinaciji s kirurgijo pri oralnih in kožnih tumorjih psov (Slovene)   7/1/2014 - 6/30/2017  PhD Maja Čemažar   5,190 
19. J3-5505  Elektrokemoterapija globoko ležečih tumorjev (Slovene)   8/1/2013 - 7/31/2016  PhD Gregor Serša   4,555 
20. J3-4211  Antiangiogena genska terapija raka: tarčno zdravljenje z uporabo elektroporacije in magnetnih nanodelcev kot dostavnih sistemov (Slovene)   7/1/2011 - 6/30/2014  PhD Gregor Serša   6,891 
21. J1-4044  Apoptotično delovanje alkilpiridinijevih spojin na celice pljučnega adenokarcinoma (Slovene)   7/1/2011 - 6/30/2014  PhD Tom Turk   6,673 
22. J3-4259  Priprava in validacija terapevtskih plazmidov brez selekcijskega gena za antibiotično rezistenco za gensko terapijo raka z inducibilnimi in tkivno specifičnimi promotorji (Slovene)   7/1/2011 - 6/30/2014  PhD Maja Čemažar   6,296 
23. J1-4131  Sinteza, karakterizacija in uporaba novih rutenijevih spojin v elektrokemoterapiji tumorjev (Slovene)   7/1/2011 - 6/30/2014  PhD Iztok Turel   6,384 
24. J3-4176  Predklinične raziskave elektrogenske terapije v onkologiji (Slovene)   7/1/2002 - 6/30/2005  PhD Maja Čemažar   5,082 
25. J3-3489  New biomedical applications of electroporation   7/1/2001 - 6/30/2004  PhD Gregor Serša   4,273 
26. J3-2049  Uporaba elektroporacij v genski terapiji (Slovene)   1/1/2000 - 6/30/2002  PhD Maja Čemažar   4,334 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head No. of publications
1. P3-0003  Development and evaluation of new approaches to cancer treatment   1/1/2022 - 12/31/2027 PhD Gregor Serša   4,393 
2. P3-0003  Development and evaluation of new approaches to cancer treatment   1/1/2015 - 12/31/2021 PhD Gregor Serša   3,528 
3. P3-0003  Development and evaluation of new approaches to cancer treatment   1/1/2009 - 12/31/2014 PhD Gregor Serša   4,296 
4. P3-0003  Development and evaluation of new approaches to cancer treatment   7/1/2004 - 12/31/2008 PhD Gregor Serša   3,282 
Views history
Favourite